Blenrep Injection, Powder, For Solution
Product Images NDC 0173-0913

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Blenrep (NDC 0173-0913). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Belantamab Mafodotin-blmf Chemical Structure (Blenrep Spl Graphic 01)

Belantamab Mafodotin-blmf Chemical Structure (Blenrep Spl Graphic 01)
Chemical structure diagram illustrating the mcMMAF molecule conjugated to a monoclonal antibody (mAb) as part of the belantamab mafodotin antibody-drug conjugate.*
FDA Label Image

Figure 1 (Blenrep Spl Graphic 02)

Figure 1 (Blenrep Spl Graphic 02)
A Kaplan-Meier survival curve graph depicting progression-free survival probability over time in months since randomization. It compares two treatment groups: BLENREP plus bortezomib/dexamethasone (solid line) and Daratumumab plus bortezomib/dexamethasone (dashed line). The graph includes numbers at risk and event counts at time intervals for each group.*
FDA Label Image

Figure 2 (Blenrep Spl Graphic 03)

Figure 2 (Blenrep Spl Graphic 03)
A Kaplan-Meier curve chart showing overall survival probability over time in months since randomization for two treatment groups: BLENREP + bortezomib/dexamethasone and Daratumumab + bortezomib/dexamethasone. The chart includes a survival probability y-axis and time x-axis, with numbers at risk and number of events displayed below.*
FDA Label Image

Blenrep 70 mg Per Vial Carton (Blenrep Spl Graphic 04)

Blenrep 70 mg Per Vial Carton (Blenrep Spl Graphic 04)
Label for Blenrep (belantamab mafodotin-blmf) injection, powder for solution administered intravenously. The vial strength is 70 mg per vial. Label includes warnings about hazardous drug status, dispensing medication guide to patients, no preservative, and single-dose vial instructions. Labeler is GlaxoSmithKline LLC, with NDC 0173-0913-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.